[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Express Diagnostics Int'l., Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":75},{"warningLetters":4,"total":74},[5,31,55],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},21693,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-01T04:00:00Z\">09\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdiagnostics-llc-730301-09012026\">O.N. Diagnostics, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Medical Device Reporting\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Shui Wong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>O.N. Diagnostics, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1936 University Ave, Ste 280\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Berkley\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94704\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS 730301\u003C\u002Fp>\u003Cp>9\u002F1\u002F2026\u003C\u002Fp>\u003Cp>Dear Ms. Wong,\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Berkley, CA, from March 12-17, 2026, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures (or markets) the VirtuOst and VirtuOst Vertebral Fracture Assessment (VFA) software products. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. The VirtuOst and VirtuOst VFA software products are device software functions because they analyze medical images for use in the diagnosis of existing vertebral fractures and the management of osteoporosis. As such, your firm has responsibility for maintaining full compliance with all applicable pre- and post-market requirements associated with these device software functions.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that the VirtuOst VFA 3.0.0 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The VirtuOst VFA 3.0.0 is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with changes or modifications in the device that could significantly affect the safety or effectiveness of the device without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>Specifically, the VirtuOst VFA was cleared under K171435 with the following indications: VirtuOst VFA uses sagittal sections from a spine-containing CT scan, with or without contrast enhancement, to visualize and measure vertebral deformities, classify the type and grade of any existing vertebral fracture, and from this identify patients at high risk of a future osteoporosis-related fracture. This information can be interpreted by a physician to diagnose existing vertebral fractures and to manage patients for osteoporosis.\u003C\u002Fp>\u003Cp>A review of the Software Version Control Log and “3.0.0 Release Notes” dated June 11, 2024, shows that a new machine learning algorithm was introduced for vertebral landmarking. A new model trained on different data, with different architecture, or optimized for a different objective may perform differently across patient populations, imaging equipment types, or clinical settings. This new feature fundamentally changes how the device performs, fails, and affects patients in ways that go beyond what was originally cleared and therefore the feature must be adequately validated. Inadequate validation of this new feature may lead to a device that is unable to perform clinically as expected, which may result in patient harm such as missed or inadequate diagnosis, absence or delay of results, leading to missing, inaccurate, or delayed patient assessment. It can also lead to incorrect patient management due to misinterpretation of device output or overreliance on device output for radiological image interpretation. Thus, a new premarket notification is required.\u003C\u002Fp>\u003Cp>Additionally, the VirtuOst VFA 3.0.0 version involves two other changes that each independently raise significant regulatory concerns. First, the device has migrated from a desktop application to a web-based architecture, which introduces network-exposed attack surfaces, authentication vulnerabilities, and other cybersecurity risks inherent to internet-accessible platforms. As your firm acknowledged during the inspection, the change from a desktop application to a web-based architecture expanded the “cyberattack surface area.” Second, the technology platform has been migrated from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> only, which necessitates comprehensive re-verification and re-validation of the entire software codebase, including changes to third-party libraries and dependencies. FDA has not reviewed your device's Software Bill of Materials (SBOM) or documentation of third-party components affected by this migration.\u003C\u002Fp>\u003Cp>Each of these changes could significantly affect the safety or effectiveness of the device by introducing new software and cybersecurity risks. Furthermore, these changes require a new premarket notification pursuant to 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Our office requests that O.N. Diagnostics cease any activities that result in the misbranding or adulteration of the VirtuOst VFA 3.0.0, such as the commercial distribution of the device for the uses discussed above.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality Management System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. We received a response from Dr. Kopperdahl, Director of Research and Development, dated April 1, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to document procedures for corrective actions and take action to eliminate the cause of nonconformities in order to prevent recurrence, as required by ISO 13485:2016, Clause 8.5.2.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Review of your CAPA procedure, DOC: SOP-017, and related records found:\u003C\u002Fp>\u003Cp>A. Failure to take necessary corrective actions without undue delay. For example:\u003C\u002Fp>\u003Cp>i. Within CAPA-0080, procedural updates from four other CAPA records identified as necessary to eliminate the cause of nonconformities and prevent their recurrence were not made for over a year and a half.\u003C\u002Fp>\u003Cp>ii. Additionally, your organization was made aware of the underlying issue related to the need to update your \u003Cstrong>(b)(4)\u003C\u002Fstrong> software three times over three years. Although CAPA-0088 was opened the day before our inspection began to address this three yearlong software issue, it was unsigned (even to demonstrate opening a new record) and no corrective actions had been identified or initiated within the record.\u003C\u002Fp>\u003Cp>B. Failure to clearly define the requirements to evaluate the need for action to ensure that nonconformities do not recur. For example:\u003C\u002Fp>\u003Cp>i. Your procedure allows use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ticket instead of a corrective action when there are “Individual and sporadic instances of issues that need correction do not require a CAPA”. This is one reason for some of the untimely corrective actions discussed in item A above. The procedure needs to more clearly define when a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ticket may be used vs. opening a CAPA to ensure corrective action is taken appropriately.\u003C\u002Fp>\u003Cp>ii. Your organization has changed the requirements used to evaluate the need for action \u002F determine when a corrective action is necessary. CAPA-0083 included a corrective action to update to your CAPA procedure. Your findings stated the language governing when a CAPA should be opened was too broad and did not include the potential for process based CAPAs to be opened. The language targeted for update stated, “In general, a CAPA investigation will be initiated for any quality problem that is a non-conformance with respect to medical device requirements that has an associated safety hazard.”\u003C\u002Fp>\u003Cp>Therefore, in revision 11 released 10\u002F2\u002F2024, your organization implemented a change to “narrow the CAPA triggers and place more emphasis on systemic or recurring issues”. This update also included allowance to document other issues as a \u003Cstrong>(b)(4)\u003C\u002Fstrong> ticket, as previously mentioned above. These changes altered the threshold of when to open a CAPA from a safety hazard focus to systemic issues and allowed more flexibility to handle “individual and sporadic instances” through the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. In doing so, it appears your procedure now lacks clarity for when it is necessary to open a corrective action, based on risk.\u003C\u002Fp>\u003Cp>Additionally, the impact of these changes was not evaluated prior to implementation. To maintain the integrity of the QMS, all changes must be evaluated to determine their potential impact on it. This evaluation must be conducted before implementing the change.\u003C\u002Fp>\u003Cp>C. Failure to require documentation of verification of effectiveness following corrective action implementation.\u003C\u002Fp>\u003Cp>The procedure allows closure after “A failure investigation has been completed, a corrective action has been defined and implemented, and the effectiveness of the implemented action has been evaluated.”\u003C\u002Fp>\u003Cp>Within CAPA-0080, the record includes verification of implementation, but not of effectiveness. There is no developed plan to determine how to verify effectiveness or a place to do so within the form, only a yes \u002F no checkbox.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response regarding items 1A and C above and conclude that it is not adequate. We understand your intent is to update the CAPA procedure to “strengthen requirements for effectiveness verification, including predefined acceptance criteria and sufficient prospective evidence, to ensure nonconformities do not recur”, as well as train staff, conduct a retrospective review to include performing additional analysis where necessary, and document findings. You anticipate an overall timeline of 90 days to complete all these steps (early August 2026). The CAPA documenting these actions will be closed when 100% of CAPAs over a six-month period and at least three CAPAs have demonstrated correct implementation of the revised procedure. This overall approach seems reasonable, however your response is inadequate because the requirement of ensuring necessary corrective actions are taken without undue delay has not been addressed to complete necessary procedural updates, and no records were provided for evidence of implementation of corrective actions.\u003C\u002Fp>\u003Cp>Your response related to item 1B states you intend to require documented risk assessments prior to implementation as part of change control procedures, establish criteria for when a change is ‘critical’ or ALARP, create a new form for this assessment following ISO 14971, train staff, perform a retrospective review of QMS changes over the last six months and act on those that meet new criteria, and summarize findings. You estimate all these actions to take about 90 days (early August 2026) and state this CAPA will be closed if no recurrence over a six-month period defined as failure to identify critical process changes or perform risk assessments of those changes. The adequacy of your response to item 1B cannot be determined as no records were provided for evidence of implementation of corrective actions.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to adequately document procedures to ensure that purchased product conforms to specified purchasing information and plan the monitoring and re-evaluation of suppliers, as required by 21 CFR 820, ISO 13485: 2016 Clause 7.4.1.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For example: the procedural requirements in your organization’s Purchasing Controls procedure, rev 11, concerning how your firm will re-evaluate and conduct monitoring and trending of suppliers \u002F vendors is vague. Specifically, none of these give details of when action should be taken. For example, the procedure mentions re-evaluation frequency will be every \u003Cstrong>(b)(4)\u003C\u002Fstrong> which maybe increased based on the criticality, but gives no specific criteria or examples of when this should occur. Regarding monitoring the procedure, it discusses “periodic progress reports and incremental deliverables” but doesn’t explain when they should be run or how those will be assessed. The extent of monitoring should be commensurate with the risk of the device, or impact on the device or QMS. The procedure also mentions trending of vendor performance but contains no limits or criteria stating when action might be necessary.\u003C\u002Fp>\u003Cp>This was discussed during your recent inspection, but as it was not cited in the 483, your response did not address this violation.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Our inspection (also) revealed that your firm has failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For example, during the inspection, your organization presented the document titled “Complaint Management Procedure”, SOP-014, Revision 15, dated January 15, 2026, as its guidance for MDR reporting. Specifically, the purpose and scope of the procedure highlights that the SOP is intended to address the requirements of 21 CFR 803. However, after reviewing the procedure, the following deficiencies were noted:\u003C\u002Fp>\u003Cp>1. Your procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1).\u003C\u002Fp>\u003Cp>a. Your procedure does not include adequate definitions of what constitutes a reportable event under 21 CFR Part 803. The fact that the procedure does not include definitions from 21 CFR 803.3 for the terms “become aware” and “caused or contributed”, and the definition described in 21 CFR 803.20(c)(1) for the term “reasonably suggests”, may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\u003C\u002Fp>\u003Cp>b. Your procedure’s definition of “serious injury” is not consistent with 21 CFR 803.3(w) and will not allow you to correctly identify complaints as reportable events.\u003C\u002Fp>\u003Cp>Specifically, DC03055, MDR Reportability Review Memorandum 4 the regulatory definition includes both injury and illness, whereas the procedure limits the definition to injury only.\u003C\u002Fp>\u003Cp>2. Your procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\u003C\u002Fp>\u003Cp>a. Instructions for submitting information that corresponds generally to the format of Form FDA 3500A, including how you will ensure that all information reasonably known to you is submitted for each event. Specifically, which types of information corresponding generally to the format of Form 3500A will need to be submitted, including the information in your firm’s possession when the initial report is filed and any required information later obtained that was not available when the initial report is filed.\u003C\u002Fp>\u003Cp>b. Instructions for complying with the 21 CFR 803.12(a) requirement to submit reports to FDA in an electronic format that the FDA can process, review, and archive.\u003C\u002Fp>\u003Cp>3. Your organization’s MDR event files do not contain all documentation of its deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable under 21 CFR Part 803, as required under 21 CFR 803.18(b)(1)(i). Specifically, although Sections 2.2 and 2.3 of the procedure describe documentation requirements, your firm’s ONG-FRM-007 Event Report reviewed for Event 0047 did not demonstrate implementation of these requirements for reportability determination.\u003C\u002Fp>\u003Cp>A device is deemed to be misbranded under section 501(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information respecting a device required by or under section 519 of the Act, 21 U.S.C. § 360i, including adverse event reports required under CFR Part 803.\u003C\u002Fp>\u003Cp>Your firm’s response dated April 1, 2026, does not address the procedural deficiencies, given that such deficiencies were not cited on the FDA 483.\u003C\u002Fp>\u003Cp>We also note your organization’s SOP-014 procedure includes references to baseline reports in Section 4.4. Baseline reports are no longer required, and we recommend that all references to a Baseline Report be removed from your firm’s MDR procedure; see: 73 Federal Register Notice 53686, dated September 17, 2008.\u003C\u002Fp>\u003Cp>Additionally, we recommend your organization establish an active Electronic Submission Gateway Next Generation (ESG NextGen) production account for the electronic submission of MDR reports. FDA verified that, as of April 24, 2026, your firm does not have such an account. Information about the ESG NextGen can be found at: Electronic Submissions Gateway Next Generation (ESG NextGen) | FDA.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Jeff Wooley at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 730301” when replying. If you have any questions about the contents of this letter, please contact: Lauren Priest at Lauren.Priest@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nShui Wong\n\nRecipient Title\n\nCEO\n\nO.N. Diagnostics, LLC\n\n1936 University Ave, Ste 280\n\nBerkley, CA 94704\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS 730301\n9\u002F1\u002F2026\nDear Ms. Wong,\nDuring an inspection of your firm located in Berkley, CA, from March 12-17, 2026, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures (or markets) the VirtuOst and VirtuOst Vertebral Fracture Assessment (VFA) software products. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. The VirtuOst and VirtuOst VFA software products are device software functions because they analyze medical images for use in the diagnosis of existing vertebral fractures and the management of osteoporosis. As such, your firm has responsibility for maintaining full compliance with all applicable pre- and post-market requirements associated with these device software functions.\nUnapproved Device Violation(s)\nOur inspection revealed that the VirtuOst VFA 3.0.0 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The VirtuOst VFA 3.0.0 is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution this device with changes or modifications in the device that could significantly affect the safety or effectiveness of the device without submitting a new premarket notification to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(i).\nSpecifically, the VirtuOst VFA was cleared under K171435 with the following indications: VirtuOst VFA uses sagittal sections from a spine-containing CT scan, with or without contrast enhancement, to visualize and measure vertebral deformities, classify the type and grade of any existing vertebral fracture, and from this identify patients at high risk of a future osteoporosis-related fracture. This information can be interpreted by a physician to diagnose existing vertebral fractures and to manage patients for osteoporosis.\nA review of the Software Version Control Log and “3.0.0 Release Notes” dated June 11, 2024, shows that a new machine learning algorithm was introduced for vertebral landmarking. A new model trained on different data, with different architecture, or optimized for a different objective may perform differently across patient populations, imaging equipment types, or clinical settings. This new feature fundamentally changes how the device performs, fails, and affects patients in ways that go beyond what was originally cleared and therefore the feature must be adequately validated. Inadequate validation of this new feature may lead to a device that is unable to perform clinically as expected, which may result in patient harm such as missed or inadequate diagnosis, absence or delay of results, leading to missing, inaccurate, or delayed patient assessment. It can also lead to incorrect patient management due to misinterpretation of device output or overreliance on device output for radiological image interpretation. Thus, a new premarket notification is required.\nAdditionally, the VirtuOst VFA 3.0.0 version involves two other changes that each independently raise significant regulatory concerns. First, the device has migrated from a desktop application to a web-based architecture, which introduces network-exposed attack surfaces, authentication vulnerabilities, and other cybersecurity risks inherent to internet-accessible platforms. As your firm acknowledged during the inspection, the change from a desktop application to a web-based architecture expanded the “cyberattack surface area.” Second, the technology platform has been migrated from (b)(4) to (b)(4) only, which necessitates comprehensive re-verification and re-validation of the entire software codebase, including changes to third-party libraries and dependencies. FDA has not reviewed your device's Software Bill of Materials (SBOM) or documentation of third-party components affected by this migration.\nEach of these changes could significantly affect the safety or effectiveness of the device by introducing new software and cybersecurity risks. Furthermore, these changes require a new premarket notification pursuant to 21 CFR 807.81(a)(3)(i).\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nOur office requests that O.N. Diagnostics cease any activities that result in the misbranding or adulteration of the VirtuOst VFA 3.0.0, such as the commercial distribution of the device for the uses discussed above.\nQuality Management System Regulation Violation(s)\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality Management System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Dr. Kopperdahl, Director of Research and Development, dated April 1, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to document procedures for corrective actions and take action to eliminate the cause of nonconformities in order to prevent recurrence, as required by ISO 13485:2016, Clause 8.5.2.\nReview of your CAPA procedure, DOC: SOP-017, and related records found:\nA. Failure to take necessary corrective actions without undue delay. For example:\ni. Within CAPA-0080, procedural updates from four other CAPA records identified as necessary to eliminate the cause of nonconformities and prevent their recurrence were not made for over a year and a half.\nii. Additionally, your organization was made aware of the underlying issue related to the need to update your (b)(4) software three times over three years. Although CAPA-0088 was opened the day before our inspection began to address this three yearlong software issue, it was unsigned (even to demonstrate opening a new record) and no corrective actions had been identified or initiated within the record.\nB. Failure to clearly define the requirements to evaluate the need for action to ensure that nonconformities do not recur. For example:\ni. Your procedure allows use of a (b)(4) ticket instead of a corrective action when there are “Individual and sporadic instances of issues that need correction do not require a CAPA”. This is one reason for some of the untimely corrective actions discussed in item A above. The procedure needs to more clearly define when a (b)(4) ticket may be used vs. opening a CAPA to ensure corrective action is taken appropriately.\nii. Your organization has changed the requirements used to evaluate the need for action \u002F determine when a corrective action is necessary. CAPA-0083 included a corrective action to update to your CAPA procedure. Your findings stated the language governing when a CAPA should be opened was too broad and did not include the potential for process based CAPAs to be opened. The language targeted for update stated, “In general, a CAPA investigation will be initiated for any quality problem that is a non-conformance with respect to medical device requirements that has an associated safety hazard.”\nTherefore, in revision 11 released 10\u002F2\u002F2024, your organization implemented a change to “narrow the CAPA triggers and place more emphasis on systemic or recurring issues”. This update also included allowance to document other issues as a (b)(4) ticket, as previously mentioned above. These changes altered the threshold of when to open a CAPA from a safety hazard focus to systemic issues and allowed more flexibility to handle “individual and sporadic instances” through the (b)(4) system. In doing so, it appears your procedure now lacks clarity for when it is necessary to open a corrective action, based on risk.\nAdditionally, the impact of these changes was not evaluated prior to implementation. To maintain the integrity of the QMS, all changes must be evaluated to determine their potential impact on it. This evaluation must be conducted before implementing the change.\nC. Failure to require documentation of verification of effectiveness following corrective action implementation.\nThe procedure allows closure after “A failure investigation has been completed, a corrective action has been defined and implemented, and the effectiveness of the implemented action has been evaluated.”\nWithin CAPA-0080, the record includes verification of implementation, but not of effectiveness. There is no developed plan to determine how to verify effectiveness or a place to do so within the form, only a yes \u002F no checkbox.\nWe reviewed your firm’s response regarding items 1A and C above and conclude that it is not adequate. We understand your intent is to update the CAPA procedure to “strengthen requirements for effectiveness verification, including predefined acceptance criteria and sufficient prospective evidence, to ensure nonconformities do not recur”, as well as train staff, conduct a retrospective review to include performing additional analysis where necessary, and document findings. You anticipate an overall timeline of 90 days to complete all these steps (early August 2026). The CAPA documenting these actions will be closed when 100% of CAPAs over a six-month period and at least three CAPAs have demonstrated correct implementation of the revised procedure. This overall approach seems reasonable, however your response is inadequate because the requirement of ensuring necessary corrective actions are taken without undue delay has not been addressed to complete necessary procedural updates, and no records were provided for evidence of implementation of corrective actions.\nYour response related to item 1B states you intend to require documented risk assessments prior to implementation as part of change control procedures, establish criteria for when a change is ‘critical’ or ALARP, create a new form for this assessment following ISO 14971, train staff, perform a retrospective review of QMS changes over the last six months and act on those that meet new criteria, and summarize findings. You estimate all these actions to take about 90 days (early August 2026) and state this CAPA will be closed if no recurrence over a six-month period defined as failure to identify critical process changes or perform risk assessments of those changes. The adequacy of your response to item 1B cannot be determined as no records were provided for evidence of implementation of corrective actions.\n2. Failure to adequately document procedures to ensure that purchased product conforms to specified purchasing information and plan the monitoring and re-evaluation of suppliers, as required by 21 CFR 820, ISO 13485: 2016 Clause 7.4.1.\nFor example: the procedural requirements in your organization’s Purchasing Controls procedure, rev 11, concerning how your firm will re-evaluate and conduct monitoring and trending of suppliers \u002F vendors is vague. Specifically, none of these give details of when action should be taken. For example, the procedure mentions re-evaluation frequency will be every (b)(4) which maybe increased based on the criticality, but gives no specific criteria or examples of when this should occur. Regarding monitoring the procedure, it discusses “periodic progress reports and incremental deliverables” but doesn’t explain when they should be run or how those will be assessed. The extent of monitoring should be commensurate with the risk of the device, or impact on the device or QMS. The procedure also mentions trending of vendor performance but contains no limits or criteria stating when action might be necessary.\nThis was discussed during your recent inspection, but as it was not cited in the 483, your response did not address this violation.\nMedical Device Reporting (MDR) Violation(s)\nOur inspection (also) revealed that your firm has failed to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17.\nFor example, during the inspection, your organization presented the document titled “Complaint Management Procedure”, SOP-014, Revision 15, dated January 15, 2026, as its guidance for MDR reporting. Specifically, the purpose and scope of the procedure highlights that the SOP is intended to address the requirements of 21 CFR 803. However, after reviewing the procedure, the following deficiencies were noted:\n1. Your procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1).\na. Your procedure does not include adequate definitions of what constitutes a reportable event under 21 CFR Part 803. The fact that the procedure does not include definitions from 21 CFR 803.3 for the terms “become aware” and “caused or contributed”, and the definition described in 21 CFR 803.20(c)(1) for the term “reasonably suggests”, may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).\nb. Your procedure’s definition of “serious injury” is not consistent with 21 CFR 803.3(w) and will not allow you to correctly identify complaints as reportable events.\nSpecifically, DC03055, MDR Reportability Review Memorandum 4 the regulatory definition includes both injury and illness, whereas the procedure limits the definition to injury only.\n2. Your procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3). Specifically, the procedure does not include:\na. Instructions for submitting information that corresponds generally to the format of Form FDA 3500A, including how you will ensure that all information reasonably known to you is submitted for each event. Specifically, which types of information corresponding generally to the format of Form 3500A will need to be submitted, including the information in your firm’s possession when the initial report is filed and any required information later obtained that was not available when the initial report is filed.\nb. Instructions for complying with the 21 CFR 803.12(a) requirement to submit reports to FDA in an electronic format that the FDA can process, review, and archive.\n3. Your organization’s MDR event files do not contain all documentation of its deliberations and decision-making processes used to determine if a device-related death, serious injury, or malfunction was or was not reportable under 21 CFR Part 803, as required under 21 CFR 803.18(b)(1)(i). Specifically, although Sections 2.2 and 2.3 of the procedure describe documentation requirements, your firm’s ONG-FRM-007 Event Report reviewed for Event 0047 did not demonstrate implementation of these requirements for reportability determination.\nA device is deemed to be misbranded under section 501(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information respecting a device required by or under section 519 of the Act, 21 U.S.C. § 360i, including adverse event reports required under CFR Part 803.\nYour firm’s response dated April 1, 2026, does not address the procedural deficiencies, given that such deficiencies were not cited on the FDA 483.\nWe also note your organization’s SOP-014 procedure includes references to baseline reports in Section 4.4. Baseline reports are no longer required, and we recommend that all references to a Baseline Report be removed from your firm’s MDR procedure; see: 73 Federal Register Notice 53686, dated September 17, 2008.\nAdditionally, we recommend your organization establish an active Electronic Submission Gateway Next Generation (ESG NextGen) production account for the electronic submission of MDR reports. FDA verified that, as of April 24, 2026, your firm does not have such an account. Information about the ESG NextGen can be found at: Electronic Submissions Gateway Next Generation (ESG NextGen) | FDA.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality Management System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Jeff Wooley at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 730301” when replying. If you have any questions about the contents of this letter, please contact: Lauren Priest at Lauren.Priest@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","O.N. Diagnostics, LLC","diagnostics-llc-730301-09012026","2026-10-14T12:31:16.41489+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdiagnostics-llc-730301-09012026","2026-11-17T01:02:03.701861+00:00","Warning Letter","Issued","2026-10-06","730301","Medical Devices","Shui Wong","2026-10-14T12:33:05.323+00:00","VIA Electronic Mail","2026-09-01",{"id":32,"raw":33,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":50,"recipient_name":51,"body_fetched_at":52,"delivery_method":53,"recipient_title":19,"reference_number":19,"action_taken_date":54,"medical_device_id":19,"response_letter_date":19},1965,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-08-01T13:20:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-20T04:00:00Z\">07\u002F20\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fiso-tex-diagnostics-inc-655666-07202023\">Iso-Tex Diagnostics, Inc.\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations II ","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail Return Confirmation Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Megan M. Maloney\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FQuality Assurance\u002FRegulatory Affairs\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Iso-Tex Diagnostics, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1511 County Road 129\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alvin\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77511\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations II \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>DATE: 7\u002F20\u002F2023\u003C\u002Fp>\n\n\u003Cp>Case #: 655666\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Maloney:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Iso-Tex Diagnostics, Inc., FEI 1626310, at 1511 County Road 129 Alvin, TX, from January 30, 2023, to February 10, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your March 2, 2023, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products of a suitable size, construction, and location to facilitate cleaning, maintenance, and proper operations (21 CFR&nbsp;\u003C\u002Fstrong>\u003Cstrong>211.42(a)). Your firm also failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas, and an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(iv) &amp; (v)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your deficient facility design, equipment suitability, and environmental conditions significantly increased contamination risk to drugs intended to be sterile.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Inadequate Design and Control of Facility Conditions\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to ensure that cleanrooms are properly designed and constructed of materials that allow for the ease of cleaning and disinfection. For example, our investigators observed:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The door of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> connection to your aseptic processing cleanroom and gowning room was in disrepair and unable to fully close.\u003C\u002Fli>\n\t\u003Cli>Foreign particulates hanging from two ceiling HEPA Filters within your aseptic processing cleanroom.\u003C\u002Fli>\n\t\u003Cli>Inadequately sealed fluorescent light fixtures in aseptic processing cleanrooms.\u003C\u002Fli>\n\t\u003Cli>Exposed electrical lightbulb sockets and an emergency light within aseptic processing cleanroom without a cover.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Inadequate Monitoring and Control of Environmental Conditions\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to ensure that your facility is designed, controlled, and maintained to prevent lower quality air from entering and contaminating your aseptic processing cleanrooms, resulting in departures from your established limits throughout your clean rooms. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Since at least December 1, 2022, negative differential pressure was frequently documented between your sterile drug processing cleanroom containing aseptic processing hoods and the adjacent gowning room, that allows for lower quality of air to move into your aseptic processing cleanroom. You lacked investigations into these recurring excursions.\u003C\u002Fli>\n\t\u003Cli>From at least August 10, 2022, you failed to maintain the relative humidity below \u003Cstrong>(b)(4)\u003C\u002Fstrong> as established in your “Environmental Quality and Control Program” procedure. Your relative humidity data reveals repetitive and extended excursions. For example, in aseptic processing cleanroom \u003Cstrong>(b)(4)\u003C\u002Fstrong>, from January 15, 2023, starting at 7:40pm, and ending January 18, 2023, at 7:10pm, the relative humidity ranged from 60.1 to 94.8%, and averaged 73.5%. Upon request for additional information on April 26, 2023, you did not provide any investigations into the excursions. You were also unable to provide procedures, use logs, or qualification documentation for a \u003Cstrong>(b)(4)\u003C\u002Fstrong> dehumidifier operating in gowning cleanroom, suite \u003Cstrong>(b)(4)\u003C\u002Fstrong>, used to control relative humidity. Your use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> dehumidifier in a cleanroom indicates a poorly designed HVAC system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Aseptic processes should be designed to minimize exposure of sterile articles to potential contamination hazards, including, but not limited to, variation in environmental conditions. It is vital for rooms of higher air cleanliness to have a substantial positive pressure differential relative to adjacent rooms of lower air cleanliness. A suitable facility monitoring system is critical to maintain appropriate environmental conditions throughout all of your cleanrooms. All deviations from established limits should be appropriately investigated to rapidly detect atypical changes that can compromise the facility’s environment. Prompt detection of an emerging problem is essential to preventing contamination of your aseptic production operations.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you fail to address systemic issues to ensure your facility is suitable for the aseptic processing for sterile drugs. You also do not provide meaningful evidence that your manufacturing environment is under an ongoing state of control.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o All human interactions within the ISO 5 area\u003Cbr>\n&nbsp; &nbsp; o Equipment placement and ergonomics\u003Cbr>\n&nbsp; &nbsp; o Air quality in the ISO 5 area and surrounding room\u003Cbr>\n&nbsp; &nbsp; o Facility layout\u003Cbr>\n&nbsp; &nbsp; o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\n\t\u003Cli>A thorough, independent assessment, and corrective action and preventive action (CAPA) for your pressure differential system and environmental temperature and humidity conditions. Include a comprehensive evaluation of monitoring, recording, alarm documentation, deviation investigation, data retention and overall system control in your assessment. Provide a CAPA that includes, but is not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o The state of control of air balance between clean areas and adequacy of integration of each of the HVAC systems\u003Cbr>\n&nbsp; &nbsp; o Documentation for all alarms, irrespective of the length or location of the event, and retention of this data\u003Cbr>\n&nbsp; &nbsp; o Remediated procedures for investigating deviations from established limits, including but not limited to specific provisions for handling instances in which a pressure reversal occurs\u003Cbr>\n&nbsp; &nbsp; o Remediated facility monitoring systems that will rapidly detect atypical changes of pressure, temperature, and humidity, in your cleanrooms simultaneously\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potential contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\t\u003Cli>Complete investigations into all batches with potential microbial contamination. The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\n\t\u003Cli>All microbial test methods and specifications used to analyze each of your drug products.\u003C\u002Fli>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\n\t\u003Cli>Your complete investigation into failed cleanroom certification study data relating to air changes. Include all original and corrected calculations regarding air changes, the location of all air inlets and exhaust outlets in the room, and a detailed description of the BSC design (e.g., intake of air) and its position in the room. You should also provide an independent assessment of the investigation, and the adequacy of air changes in all of your cleanrooms, by a qualified consult.\u003C\u002Fli>\n\t\u003Cli>Smoke studies that evaluate the suitability of your biological safety cabinets (BSC) used for the aseptic manufacturing of your drug products.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nYour firm manufactures sterile radiopharmaceutical drug products that are aseptically filled. You failed to have appropriate gowning for aseptic production of sterile injectable drug products. For example, investigators observed your production personnel:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>With exposed facial skin and hair entering your ISO 5 production environment while performing aseptic manual filling of Volumex I-131, Lot # V230102-1107.\u003C\u002Fli>\n\t\u003Cli>On multiple instances, failing to disinfect their sterile gloves before returning to the ISO 5 area.\u003C\u002Fli>\n\t\u003Cli>Use poor sterile gowning behavior and practices (e.g., sterile gown touched the floor while donning the gowning).\u003C\u002Fli>\n\t\u003Cli>Gowning without using suitable sterile gloves.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm’s failure to ensure that personnel gown appropriately and strictly adhere to acceptable aseptic procedures significantly increases the risk of drug product contamination.\u003C\u002Fp>\n\n\u003Cp>In addition, your production staff and equipment (e.g., active air monitor, analytical balance printer) blocked the path of unidirectional airflow in your ISO 5 production environment during filling operations of Volumex I-131, Lot # V230102-1107.\u003Cbr>\nUnidirectional airflow design is used to protect sterile equipment surfaces, container- closures, and drug product, and should not be obstructed by personnel or equipment. Disruption of unidirectional air in the critical area poses a significant risk to product sterility.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you do not commit to conducting a retrospective review of drug product manufactured under these conditions for potential quality and safety impact. Additionally, your response does not include supporting documentation of CAPA activities.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also, describe the frequency of quality unit oversight (e.g., audit) during aseptic processing and supporting operations.\u003C\u002Fli>\n\t\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\n\t\u003Cli>A gowning qualification program that establishes, both initially and on a periodic basis, the capability of an individual to adequately don the complete sterile gown in an aseptic manner.\u003C\u002Fli>\n\t\u003Cli>Details regarding how you will establish adequate gowning, training, gowning qualification, and supervision on an ongoing basis.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our investigators observed inadequately controlled laboratory reagents (i.e., inadequate labeling), as well as expired testing materials. The use of uncontrolled and expired testing materials may impact the validity of your testing results used to support the release of your drug products.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you do not conduct or commit to conducting an investigation to determine product impact nor do you commit to determining whether your corrective actions require extension to other related procedures.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide a comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Guidance on Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Violations and Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous warning letter, 2011-DAL-WL-03, issued on December 3, 2010, and previous inspections ending on January 31, 2018, July 10, 2015, and September 12, 2011, FDA cited similar CGMP violations and observations. You proposed specific remediation for these violations and observations in your responses. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPAs before you pursue resolution of your firm’s compliance status (i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b).\u003Cbr>\nThis also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct all violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case # \u003Cstrong>655666.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Rebecca Asente, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov, and copy Ronda Loyd-Jones, Director, Compliance Branch, at ronda.loyd-jones@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Rebecca Asente via phone at (504) 846-6104 or email at Rebecca.asente@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations, Division II\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail Return Confirmation Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMegan M. Maloney\n\nRecipient Title\n\nPresident\u002FQuality Assurance\u002FRegulatory Affairs\n\nIso-Tex Diagnostics, Inc.\n\n1511 County Road 129\n\nAlvin, TX 77511\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations II\n\nUnited States\n\nDATE: 7\u002F20\u002F2023\n\nCase #: 655666\n\nWARNING LETTER\n\nDear Ms. Maloney:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Iso-Tex Diagnostics, Inc., FEI 1626310, at 1511 County Road 129 Alvin, TX, from January 30, 2023, to February 10, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your March 2, 2023, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to have buildings used in the manufacture, processing, packing, or holding of drug products of a suitable size, construction, and location to facilitate cleaning, maintenance, and proper operations (21 CFR 211.42(a)). Your firm also failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas, and an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(iv) & (v)).\n\nYour deficient facility design, equipment suitability, and environmental conditions significantly increased contamination risk to drugs intended to be sterile.\n\nInadequate Design and Control of Facility Conditions\n\nYou failed to ensure that cleanrooms are properly designed and constructed of materials that allow for the ease of cleaning and disinfection. For example, our investigators observed:\n\nThe door of your (b)(4) connection to your aseptic processing cleanroom and gowning room was in disrepair and unable to fully close.\n\nForeign particulates hanging from two ceiling HEPA Filters within your aseptic processing cleanroom.\n\nInadequately sealed fluorescent light fixtures in aseptic processing cleanrooms.\n\nExposed electrical lightbulb sockets and an emergency light within aseptic processing cleanroom without a cover.\n\nInadequate Monitoring and Control of Environmental Conditions\n\nYou failed to ensure that your facility is designed, controlled, and maintained to prevent lower quality air from entering and contaminating your aseptic processing cleanrooms, resulting in departures from your established limits throughout your clean rooms. For example:\n\nSince at least December 1, 2022, negative differential pressure was frequently documented between your sterile drug processing cleanroom containing aseptic processing hoods and the adjacent gowning room, that allows for lower quality of air to move into your aseptic processing cleanroom. You lacked investigations into these recurring excursions.\n\nFrom at least August 10, 2022, you failed to maintain the relative humidity below (b)(4) as established in your “Environmental Quality and Control Program” procedure. Your relative humidity data reveals repetitive and extended excursions. For example, in aseptic processing cleanroom (b)(4), from January 15, 2023, starting at 7:40pm, and ending January 18, 2023, at 7:10pm, the relative humidity ranged from 60.1 to 94.8%, and averaged 73.5%. Upon request for additional information on April 26, 2023, you did not provide any investigations into the excursions. You were also unable to provide procedures, use logs, or qualification documentation for a (b)(4) dehumidifier operating in gowning cleanroom, suite (b)(4), used to control relative humidity. Your use of a (b)(4) dehumidifier in a cleanroom indicates a poorly designed HVAC system.\n\nAseptic processes should be designed to minimize exposure of sterile articles to potential contamination hazards, including, but not limited to, variation in environmental conditions. It is vital for rooms of higher air cleanliness to have a substantial positive pressure differential relative to adjacent rooms of lower air cleanliness. A suitable facility monitoring system is critical to maintain appropriate environmental conditions throughout all of your cleanrooms. All deviations from established limits should be appropriately investigated to rapidly detect atypical changes that can compromise the facility’s environment. Prompt detection of an emerging problem is essential to preventing contamination of your aseptic production operations.\n\nYour response is inadequate because you fail to address systemic issues to ensure your facility is suitable for the aseptic processing for sterile drugs. You also do not provide meaningful evidence that your manufacturing environment is under an ongoing state of control.\n\nIn response to this letter, provide:\n\nA comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area\n\no Equipment placement and ergonomics\n\no Air quality in the ISO 5 area and surrounding room\n\no Facility layout\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\n\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\n\nA thorough, independent assessment, and corrective action and preventive action (CAPA) for your pressure differential system and environmental temperature and humidity conditions. Include a comprehensive evaluation of monitoring, recording, alarm documentation, deviation investigation, data retention and overall system control in your assessment. Provide a CAPA that includes, but is not limited to:\n\no The state of control of air balance between clean areas and adequacy of integration of each of the HVAC systems\n\no Documentation for all alarms, irrespective of the length or location of the event, and retention of this data\n\no Remediated procedures for investigating deviations from established limits, including but not limited to specific provisions for handling instances in which a pressure reversal occurs\n\no Remediated facility monitoring systems that will rapidly detect atypical changes of pressure, temperature, and humidity, in your cleanrooms simultaneously\n\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\n\nA detailed risk assessment addressing the hazards posed by distributing drug products with potential contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\n\nComplete investigations into all batches with potential microbial contamination. The investigations should detail your findings regarding the root causes of the contamination.\n\nAll microbial test methods and specifications used to analyze each of your drug products.\n\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\n\nYour complete investigation into failed cleanroom certification study data relating to air changes. Include all original and corrected calculations regarding air changes, the location of all air inlets and exhaust outlets in the room, and a detailed description of the BSC design (e.g., intake of air) and its position in the room. You should also provide an independent assessment of the investigation, and the adequacy of air changes in all of your cleanrooms, by a qualified consult.\n\nSmoke studies that evaluate the suitability of your biological safety cabinets (BSC) used for the aseptic manufacturing of your drug products.\n\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nYour firm manufactures sterile radiopharmaceutical drug products that are aseptically filled. You failed to have appropriate gowning for aseptic production of sterile injectable drug products. For example, investigators observed your production personnel:\n\nWith exposed facial skin and hair entering your ISO 5 production environment while performing aseptic manual filling of Volumex I-131, Lot # V230102-1107.\n\nOn multiple instances, failing to disinfect their sterile gloves before returning to the ISO 5 area.\n\nUse poor sterile gowning behavior and practices (e.g., sterile gown touched the floor while donning the gowning).\n\nGowning without using suitable sterile gloves.\n\nYour firm’s failure to ensure that personnel gown appropriately and strictly adhere to acceptable aseptic procedures significantly increases the risk of drug product contamination.\n\nIn addition, your production staff and equipment (e.g., active air monitor, analytical balance printer) blocked the path of unidirectional airflow in your ISO 5 production environment during filling operations of Volumex I-131, Lot # V230102-1107.\n\nUnidirectional airflow design is used to protect sterile equipment surfaces, container- closures, and drug product, and should not be obstructed by personnel or equipment. Disruption of unidirectional air in the critical area poses a significant risk to product sterility.\n\nYour response is inadequate because you do not commit to conducting a retrospective review of drug product manufactured under these conditions for potential quality and safety impact. Additionally, your response does not include supporting documentation of CAPA activities.\n\nIn response to this letter, provide:\n\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also, describe the frequency of quality unit oversight (e.g., audit) during aseptic processing and supporting operations.\n\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\n\nA gowning qualification program that establishes, both initially and on a periodic basis, the capability of an individual to adequately don the complete sterile gown in an aseptic manner.\n\nDetails regarding how you will establish adequate gowning, training, gowning qualification, and supervision on an ongoing basis.\n\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nOur investigators observed inadequately controlled laboratory reagents (i.e., inadequate labeling), as well as expired testing materials. The use of uncontrolled and expired testing materials may impact the validity of your testing results used to support the release of your drug products.\n\nYour response is inadequate because you do not conduct or commit to conducting an investigation to determine product impact nor do you commit to determining whether your corrective actions require extension to other related procedures.\n\nIn response to this letter, provide a comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\nAdditional Guidance on Aseptic Processing\n\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nRepeat Violations and Observations at Facility\n\nIn a previous warning letter, 2011-DAL-WL-03, issued on December 3, 2010, and previous inspections ending on January 31, 2018, July 10, 2015, and September 12, 2011, FDA cited similar CGMP violations and observations. You proposed specific remediation for these violations and observations in your responses. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPAs before you pursue resolution of your firm’s compliance status (i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b).\n\nThis also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect all violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to case # 655666.\n\nPlease electronically submit your reply, on company letterhead, to Rebecca Asente, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov, and copy Ronda Loyd-Jones, Director, Compliance Branch, at ronda.loyd-jones@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Rebecca Asente via phone at (504) 846-6104 or email at Rebecca.asente@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations, Division II","Iso-Tex Diagnostics, Inc.","iso-tex-diagnostics-inc-655666-07202023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fiso-tex-diagnostics-inc-655666-07202023","2026-10-26T08:09:01.407758+00:00","2023-08-01","655666","Drugs","Division of Pharmaceutical Quality Operations II","Megan M. Maloney","2026-08-20T00:50:01.064+00:00","Via Electronic Mail Return Confirmation Requested","2023-07-20",{"id":56,"raw":57,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":71,"body_fetched_at":72,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},2276,[58,59,60,11,61,13,13,13],"\u003Ctime datetime=\"2022-12-27T14:20:00Z\">12\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-10-06T04:00:00Z\">10\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fempowered-diagnostics-llc-638164-10062022\">Empowered Diagnostics LLC\u003C\u002Fa>","Unapproved Products Related to the Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Rick J. Hennessey\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Empowered Diagnostics LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3341 W. McNab Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pompano Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33069\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rick@empdx.net\"> rick@empdx.net\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 638164\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 6, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Hennessey:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 3341 W. McNab Rd., Pompano Beach, Florida on February 3 through February 25, 2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer and distributor of the CovClear COVID-19 Rapid Antigen Tests and the ImmunoPass COVID-19 Neutralizing Antibody Rapid Tests (hereinafter collectively referred to as “COVID-19 Test Kits”). Based on our review, your COVID-19 Test Kits are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that these COVID-19 Test Kits have been distributed in the U.S. without marketing approval, clearance, or authorization from FDA. Accordingly, the products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C §331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>Your ImmunoPass COVID-19 Neutralizing Antibody Rapid Tests and certain configurations of your CovClear COVID-19 Rapid Antigen Tests are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that these products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>. In addition, the guidance titled “\u003Cstrong>Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)\u003C\u002Fstrong>”\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The violations observed are cited below.\u003C\u002Fp>\n\n\u003Cp>We received your responses dated March 18, 2022; April 8, 2022; April 15, 2022; and April 29, 2022, concerning our investigator(s) observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm on February 28, 2022. We address your responses below.\u003C\u002Fp>\n\n\u003Cp>Your response dated March 18, 2022, indicated that you are a small start-up seeking to market and distribute COVID-19 devices under Emergency Use Authorization in the United States. Your response references the FDA guidance document, “\u003Cem>Emergency Use Authorization of Medical Products and Related Authorities, Guidance for Industry and other Stakeholders\u003C\u002Fem>” issued January 2017 and that FDA may waive cGMPs on a case-by-case basis, and your response goes on to list some examples for products similar to your COVID-19 testing products. The guidance document that you have referenced also states “\u003Cem>FDA generally expects that EUA products will be produced, stored, and distributed in compliance with CGMPs; however, limits or waivers may be granted in an EUA on a case-by-case basis, after consideration of the circumstances and of any alternative proposed approach\u003C\u002Fem>.” However, as the devices which were distributed have not been granted EUA authorization, no such waiver of cGMPs has been granted to your firm.\u003C\u002Fp>\n\n\u003Cp>The violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and maintain design control procedures in order to ensure that specified design requirements of the device are met, as required by 21 CFR 820.30(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not establish design control procedures prior to the distribution of the CovClear COVID-19 Rapid Antigen Tests. For example, Design validation activities and\u002For their documentation for the release of the CovClear Rapid Antigen Test were inadequate. The IFU document COVCLEAR SARS-COV-2 RAPID ANTIGEN TEST, LIT 900-027 REV 1, (not dated), states in the DIRECT TEST SWAB PROCEDURE section (p. 4) to “read results within 3-20 minutes.” All the CovClear design verification and validation documentation reviewed revealed the time for reading the test results at 20 minutes.\u003C\u002Fp>\n\n\u003Cp>You must establish and maintain procedures to ensure that specified design requirements are met, this would include validating the device design to include reading results for the specified timeframe. If a user reads the results prior to the validated time, an incorrect diagnosis may result. Your design controls should ensure that the device’s specifications meet the intended use. Your response indicates that you have developed design control procedures that are compliant with the regulation. A follow-up inspection will be necessary to evaluate the effectiveness of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to adequately establish and implement corrective and preventive action procedures, as required by 21 CFR 820.100(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, during review of your corrective action activities, your firm indicated that an internal audit \u002F gap analysis was conducted by a third-party auditor from May 20-24, 2021 that revealed major nonconformances to your quality system. Your Quality Department indicated that no systematic investigation to identify root causes of these reported issues or to identify similar quality issues was conducted; no corrective action plan was defined to systematically address the root causes; and no effectiveness verifications were conducted to address the deficiencies identified by the third-party auditor.\u003C\u002Fp>\n\n\u003Cp>Your response indicates that you have developed procedures that are to be compliant with the regulation and have conducted training. A follow-up inspection will be necessary to evaluate the effectiveness of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your procedure QP 822, CUSTOMER FEEDBACK AND COMPLAINT HANDLING, Revision A, Effective June 22, 2020 until June 29, 2021 (Revision B) was inadequate in that the procedure did not include the requirement for complaints to be evaluated to determine whether the complaint is reportable. Additionally, a review of your complaint handling activities revealed that the contact phone number provided in your IFUs was directed to a commercial phone answering system monitored by the Marketing Department. There was no documentation of any follow-up with callers to determine if the inquiries constituted complaints. There were two notification transcriptions dated October 7, 2021 and October 14, 2021 that appeared to require further investigation and were not forwarded to QA for investigation or evaluation of reportability.\u003C\u002Fp>\n\n\u003Cp>We acknowledge you have revised your procedure and have conducted training. A follow-up inspection will need to be conducted to evaluate the implementation and the effectiveness of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to adequately establish procedures for finished device acceptance, as required by 21 CFR 820.80(d).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, Manufacturing Batch Record, MBR 900-005, Final QC Testing for Antigen Test which covers production lot number 02-365-03, lot size 1,270 kits\u002F 50 test strips with expiration dates of February 14, 2021 and June 2022 did not demonstrate the lot met the acceptance criteria for release, and this lot was distributed to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Your response indicates you have identified the root cause to be inadequate procedures lacking clearly defined acceptance criteria in the final QC testing MBR. You indicate you have updated the procedures, forms, and acceptance criteria, and have conducted training. Lot 02-365-03 was subject of the recall and product destruction will be documented within a CAPA. FDA witnessed the destruction on June 30, 2022. The implementation and effectiveness of your corrective actions will be reviewed during your follow-up inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to adequately establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, you did not ensure that your suppliers perform contracted processes that impact CovClear’s performance and effectiveness in a manner that guarantees your quality specifications are consistently met.\u003C\u002Fp>\n\n\u003Cp>A. The packaging process for the CovClear Rapid Antigen Test’s individually foil-wrapped configuration performed by your contract packager was not adequately validated to ensure that finished product will meet performance specifications during transportation, storage and use.\u003C\u002Fp>\n\n\u003Cp>B. Your firm indicated the Machinery Acceptance Declaration, approved August 5, 2021, used by your contract packager as the validation documentation, does not include any operating parameters, processing limits, component \u002F raw material (foil) identification, nor does it demonstrate the validation accounted for potential process variations introduced by differences in operators or packaging material lots, or how the documentation applies to the CovClear packaging.\u003C\u002Fp>\n\n\u003Cp>Your response indicates that you have retained new regulatory and legal advisors and that you have developed purchasing control procedures that are compliant with the regulation. A follow-up inspection will verify the effectiveness of your corrective actions.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to adequately establish and maintain document control procedures, as required by 21 CFR 820.40.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, your IFU document COVCLEAR SARS-COV-2 RAPID ANTIGEN TEST, LIT 900-027 REV 1, (not dated), and your marketing materials were observed to: lack the approval signature and date, the review for adequacy, and the change control within the quality system; and contain incorrect authorization status and or intended use for the CovClear Rapid Antigen Test.\u003C\u002Fp>\n\n\u003Cp>Your response indicates that you have identified the root cause and have taken corrective actions including: personnel changes and conducting a recall. You indicate that you are in compliance with the regulations. A follow-up inspection is necessary to determine the effectiveness or your corrective actions.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of federal contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-FDAs-decision-not-issue-certain-export-certificates-devices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-FDAs-decision-not-issue-certain-export-certificates-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. You should take immediate action to address any of the violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address any of these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulentcoronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulentcoronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the distribution of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>Please also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\u003C\u002Fp>\n\n\u003Cp>This response should be sent via email to: Melissa Michurski, Director of Compliance Branch, at \u003Cstrong>oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 638164\u003C\u002Fstrong> when replying.\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, \u003Cstrong>ORA Division Compliance Officer\u003C\u002Fstrong> at demetria.lueneburg@fda.hhs.gov \u003Cstrong>or 612-758-7210\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTimothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Blake Bevill, M.S.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological Health\u003Cbr>\nDivision 2 Central\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Accessible at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRick J. Hennessey\n\nRecipient Title\n\nCEO\n\nEmpowered Diagnostics LLC\n\n3341 W. McNab Rd\n\nPompano Beach, FL 33069\n\nUnited States\n\nrick@empdx.net\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 638164\n\nOctober 6, 2022\n\nDear Mr. Hennessey:\n\nDuring an inspection of your firm located at 3341 W. McNab Rd., Pompano Beach, Florida on February 3 through February 25, 2022, investigators from the United States Food and Drug Administration (FDA) determined that your firm is a medical device manufacturer and distributor of the CovClear COVID-19 Rapid Antigen Tests and the ImmunoPass COVID-19 Neutralizing Antibody Rapid Tests (hereinafter collectively referred to as “COVID-19 Test Kits”). Based on our review, your COVID-19 Test Kits are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nOur inspection revealed that these COVID-19 Test Kits have been distributed in the U.S. without marketing approval, clearance, or authorization from FDA. Accordingly, the products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C §331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nYour ImmunoPass COVID-19 Neutralizing Antibody Rapid Tests and certain configurations of your CovClear COVID-19 Rapid Antigen Tests are also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because labeling distributed with these products included statements that these products are authorized for use under an Emergency Use Authorization (EUA). These statements create a false impression that your products have been approved or authorized for emergency use by FDA and are misleading. As discussed above, none of your COVID-19 Test Kits have been approved, cleared, or authorized for emergency use by FDA.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you have distributed a product that is intended for use in mitigation, prevention, treatment, diagnosis, or cure COVID-19 in people. We request that you take immediate action to prevent distribution of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”4 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nOur inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System Regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. The violations observed are cited below.\n\nWe received your responses dated March 18, 2022; April 8, 2022; April 15, 2022; and April 29, 2022, concerning our investigator(s) observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm on February 28, 2022. We address your responses below.\n\nYour response dated March 18, 2022, indicated that you are a small start-up seeking to market and distribute COVID-19 devices under Emergency Use Authorization in the United States. Your response references the FDA guidance document, “Emergency Use Authorization of Medical Products and Related Authorities, Guidance for Industry and other Stakeholders” issued January 2017 and that FDA may waive cGMPs on a case-by-case basis, and your response goes on to list some examples for products similar to your COVID-19 testing products. The guidance document that you have referenced also states “FDA generally expects that EUA products will be produced, stored, and distributed in compliance with CGMPs; however, limits or waivers may be granted in an EUA on a case-by-case basis, after consideration of the circumstances and of any alternative proposed approach.” However, as the devices which were distributed have not been granted EUA authorization, no such waiver of cGMPs has been granted to your firm.\n\nThe violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain design control procedures in order to ensure that specified design requirements of the device are met, as required by 21 CFR 820.30(a).\n\nSpecifically, your firm did not establish design control procedures prior to the distribution of the CovClear COVID-19 Rapid Antigen Tests. For example, Design validation activities and\u002For their documentation for the release of the CovClear Rapid Antigen Test were inadequate. The IFU document COVCLEAR SARS-COV-2 RAPID ANTIGEN TEST, LIT 900-027 REV 1, (not dated), states in the DIRECT TEST SWAB PROCEDURE section (p. 4) to “read results within 3-20 minutes.” All the CovClear design verification and validation documentation reviewed revealed the time for reading the test results at 20 minutes.\n\nYou must establish and maintain procedures to ensure that specified design requirements are met, this would include validating the device design to include reading results for the specified timeframe. If a user reads the results prior to the validated time, an incorrect diagnosis may result. Your design controls should ensure that the device’s specifications meet the intended use. Your response indicates that you have developed design control procedures that are compliant with the regulation. A follow-up inspection will be necessary to evaluate the effectiveness of your corrective actions.\n\n2. Failure to adequately establish and implement corrective and preventive action procedures, as required by 21 CFR 820.100(a).\n\nSpecifically, during review of your corrective action activities, your firm indicated that an internal audit \u002F gap analysis was conducted by a third-party auditor from May 20-24, 2021 that revealed major nonconformances to your quality system. Your Quality Department indicated that no systematic investigation to identify root causes of these reported issues or to identify similar quality issues was conducted; no corrective action plan was defined to systematically address the root causes; and no effectiveness verifications were conducted to address the deficiencies identified by the third-party auditor.\n\nYour response indicates that you have developed procedures that are to be compliant with the regulation and have conducted training. A follow-up inspection will be necessary to evaluate the effectiveness of your corrective actions.\n\n3. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\n\nSpecifically, your procedure QP 822, CUSTOMER FEEDBACK AND COMPLAINT HANDLING, Revision A, Effective June 22, 2020 until June 29, 2021 (Revision B) was inadequate in that the procedure did not include the requirement for complaints to be evaluated to determine whether the complaint is reportable. Additionally, a review of your complaint handling activities revealed that the contact phone number provided in your IFUs was directed to a commercial phone answering system monitored by the Marketing Department. There was no documentation of any follow-up with callers to determine if the inquiries constituted complaints. There were two notification transcriptions dated October 7, 2021 and October 14, 2021 that appeared to require further investigation and were not forwarded to QA for investigation or evaluation of reportability.\n\nWe acknowledge you have revised your procedure and have conducted training. A follow-up inspection will need to be conducted to evaluate the implementation and the effectiveness of your corrective actions.\n\n4. Failure to adequately establish procedures for finished device acceptance, as required by 21 CFR 820.80(d).\n\nSpecifically, Manufacturing Batch Record, MBR 900-005, Final QC Testing for Antigen Test which covers production lot number 02-365-03, lot size 1,270 kits\u002F 50 test strips with expiration dates of February 14, 2021 and June 2022 did not demonstrate the lot met the acceptance criteria for release, and this lot was distributed to customers in the United States.\n\nYour response indicates you have identified the root cause to be inadequate procedures lacking clearly defined acceptance criteria in the final QC testing MBR. You indicate you have updated the procedures, forms, and acceptance criteria, and have conducted training. Lot 02-365-03 was subject of the recall and product destruction will be documented within a CAPA. FDA witnessed the destruction on June 30, 2022. The implementation and effectiveness of your corrective actions will be reviewed during your follow-up inspection.\n\n5. Failure to adequately establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\n\nSpecifically, you did not ensure that your suppliers perform contracted processes that impact CovClear’s performance and effectiveness in a manner that guarantees your quality specifications are consistently met.\n\nA. The packaging process for the CovClear Rapid Antigen Test’s individually foil-wrapped configuration performed by your contract packager was not adequately validated to ensure that finished product will meet performance specifications during transportation, storage and use.\n\nB. Your firm indicated the Machinery Acceptance Declaration, approved August 5, 2021, used by your contract packager as the validation documentation, does not include any operating parameters, processing limits, component \u002F raw material (foil) identification, nor does it demonstrate the validation accounted for potential process variations introduced by differences in operators or packaging material lots, or how the documentation applies to the CovClear packaging.\n\nYour response indicates that you have retained new regulatory and legal advisors and that you have developed purchasing control procedures that are compliant with the regulation. A follow-up inspection will verify the effectiveness of your corrective actions.\n\n6. Failure to adequately establish and maintain document control procedures, as required by 21 CFR 820.40.\n\nSpecifically, your IFU document COVCLEAR SARS-COV-2 RAPID ANTIGEN TEST, LIT 900-027 REV 1, (not dated), and your marketing materials were observed to: lack the approval signature and date, the review for adequacy, and the change control within the quality system; and contain incorrect authorization status and or intended use for the CovClear Rapid Antigen Test.\n\nYour response indicates that you have identified the root cause and have taken corrective actions including: personnel changes and conducting a recall. You indicate that you are in compliance with the regulations. A follow-up inspection is necessary to determine the effectiveness or your corrective actions.\n\nYour firm should take prompt action to address any violations. Other federal agencies may take your compliance history into account when considering the award of federal contracts. Should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. More information on processes for persons denied a CFG can be found at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-request-review-FDAs-decision-not-issue-certain-export-certificates-devices.\n\nNote, there are two response time frames specified. You should take immediate action to address any of the violations relating to your firm’s sale or distribution of the COVID-19 Test Kits and to prevent future violations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19 related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address any of these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at: https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulentcoronavirus-disease-2019-covid-19-products. Once you have taken actions to address the distribution of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nPlease also notify FDA in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter related to Quality Systems. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If any corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions your firm plans to take will require more time, please include a timetable for implementation of those activities. If any corrections and\u002For corrective actions your firm plans to take cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. We will communicate with you regarding your firm’s response(s) and any need to re-inspect your firm’s facility to verify that any appropriate corrections have been made and\u002For corrective actions have been taken.\n\nThis response should be sent via email to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 638164 when replying.\n\nIf you have any questions about the contents of this letter, please contact: Demetria Lueneburg, ORA Division Compliance Officer at demetria.lueneburg@fda.hhs.gov or 612-758-7210.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration. It is your firm’s responsibility that the products you sell are in compliance with the Act and FDA’s implementing regulations. Failure to adequately address the matters discussed in this letter may result in legal action, including without limitation, seizure, and injunction. The specific concerns noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be indicative of, or in addition to, other issues with your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any deficiencies and take prompt actions to correct any violations and bring your products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nBlake Bevill, M.S.\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological Health\n\nDivision 2 Central\n\n__________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n3 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\n\n4 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload","Empowered Diagnostics LLC","empowered-diagnostics-llc-638164-10062022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fempowered-diagnostics-llc-638164-10062022","2026-10-26T08:08:35.475486+00:00","2022-12-27","638164","Rick J. Hennessey","2026-08-20T01:20:47.784+00:00","2022-10-06",3,{"510k":76,"classification":77,"enforcement":78,"event":79,"event_backfill":80,"pma":81,"warning_letter":82},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]